Pharmaceutical - UK, Neurological

Filter

Current filters:

UKNeurological

Popular Filters

Alzheimer’s Research UK launches £30m Drug Discovery Alliance

Alzheimer’s Research UK launches £30m Drug Discovery Alliance

16-02-2015

Dementia research charity Alzheimer’s Research UK has announced a £30 million ($46 million) Drug Discovery…

Aging-associated diseasesNeurologicalPharmaceuticalResearchUK

Alzheimer's Research UK launches $31 million global clinical trials fund

Alzheimer's Research UK launches $31 million global clinical trials fund

12-12-2014

Alzheimer’s Research UK, the country’s leading dementia research charity, has launched a global clinical…

DementiaNeurologicalPharmaceuticalResearchUK

UK Prime Minister to announce £15 million dementia research fund in Autumn Statement

UK Prime Minister to announce £15 million dementia research fund in Autumn Statement

02-12-2014

The UK prime minister David Cameron is to announce a £15 million ($24 million) commitment to a new fund…

NeurologicalPharmaceuticalPoliticsResearchUK

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

The Global Crisis of Depression conference: high co-morbidity, high costs, few answers

27-11-2014

John Andrews, consultant editor of The Economist, opened the Global Crisis of Depression conference by…

InterviewsLundbeckNeurologicalPharmaceuticalResearchSocial IssuesUK

UK's NICE recommends Selincro to help reduce alcohol dependence

UK's NICE recommends Selincro to help reduce alcohol dependence

26-11-2014

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Selincro (nalmefene)…

LundbeckNeurologicalPharmaceuticalRegulationSelincroUK

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

04-11-2014

A new study has suggested that drugs currently being used to treat diabetes also have the potential to…

liraglutidelixisenatideNeurologicalNovo NordiskPharmaceuticalResearchSanofiUK

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

16-10-2014

Anglo-Swedish drug major AstraZeneca, together with its global biologics R&D arm MedImmune, has entered…

AstraZenecaNeurologicalPharmaceuticalResearchUK

NICE updates guidance for management of multiple sclerosis but does not recommend Bayer's Sativex

NICE updates guidance for management of multiple sclerosis but does not recommend Bayer's Sativex

09-10-2014

The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for the…

BayerNeurologicalPharmaceuticalRegulationSativexUK

New UK human studies funded by £60 million investment to research Parkinson’s, addiction and immunity

New UK human studies funded by £60 million investment to research Parkinson’s, addiction and immunity

07-10-2014

Three new research programs have been funded as part of a £60 million ($96 million) investment from…

NeurologicalPharmaceuticalResearchUKUnited Kingdom

NICE recommends Lundbeck’s Selincro for alcohol dependence

NICE recommends Lundbeck’s Selincro for alcohol dependence

02-10-2014

Today’s announcement that the UK’s National Institute for Health and Care Excellence (NICE) recommends…

Biotie TherapiesLundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

Latuda’s arrival better late than never for schizophrenia treatment in the UK, says analyst

12-09-2014

The recent introduction of antipsychotic drug Latuda (lurasidone) into the UK market, three years after…

Dainippon Sumitomo PharmaHealthcareLatudaMarkets & MarketingNeurologicalPharmaceuticalSunovion PharmaceuticalsUK

Norgine sells certain rights for Camcolit and Somnite to Essential Pharma

11-09-2014

Netherlands-headquartered independent drugmaker Norgine has agreed to sell all rights in the UK for Somnite…

Essential PharmaIrelandLicensingNeurologicalNorginePharmaceuticalUK

Reckitt Benckiser to spin out pharma; GSK views Consumer options

Reckitt Benckiser to spin out pharma; GSK views Consumer options

28-07-2014

UK-based consumer goods giant Reckitt Benckiser plans to spin off its USA-based pharmaceutical business,…

FinancialGlaxoSmithKlineMergers & AcquisitionsNeurologicalPharmaceuticalReckitt BenckiserSuboxoneUK

UK’s NICE backs Lundbeck drug for alcohol dependence

UK’s NICE backs Lundbeck drug for alcohol dependence

10-07-2014

In new draft guidance, the UK drug watchdog the National Institute for Health and Care Excellence (NICE)…

LundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

UK Prime Minister announces drive to discover new dementia drugs in £100 million campaign

UK Prime Minister announces drive to discover new dementia drugs in £100 million campaign

19-06-2014

The UK Prime Minister David Cameron will today pledge a new drive by the UK to discover new drugs and…

DementiaNeurologicalPharmaceuticalResearchUK

GW shares rise on positive Epidiolex efficacy data

GW shares rise on positive Epidiolex efficacy data

18-06-2014

UK-based GW Pharmaceuticals has announced physician reports of efficacy and safety data from its investigational…

epidiolexGW PharmaceuticalsNeurologicalPharmaceuticalResearchUK

GW Pharma shows drop in revenue but expects ‘steady progress’

GW Pharma shows drop in revenue but expects ‘steady progress’

07-05-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

FinancialGW PharmaceuticalsNeurologicalPharmaceuticalSativexUK

Lundbeck partners with Nanomerics for drug delivery collaboration

Lundbeck partners with Nanomerics for drug delivery collaboration

30-04-2014

UK-based drug delivery company Nanomerics, a spin out of the University College London, has announced…

Brain cancerBrain tumorCNS DiseasesDementiaLundbeckMedicineNeurologicalPharmaceuticalResearchUKUniversity College London

Phase II trial shows simvastatin slows progression of multiple sclerosis

21-03-2014

Simvastatin, the active ingredient of Merck & Co’s (NYSE: MRK) now off patent cholesterol-lowerer Zocor,…

Merck & CoNeurologicalPharmaceuticalResearchSimvastatinUK

UK Dementia Consortium to bridge the gap between academia and pharma

UK Dementia Consortium to bridge the gap between academia and pharma

11-12-2013

The UK has today announced a new £3 million ($4.9 million) Dementia Consortium bringing together research…

EisaiEli LillyNeurologicalPharmaceuticalPoliticsResearchUK

Sanofi’s Aubagio gains backing from UK’s NICE

Sanofi’s Aubagio gains backing from UK’s NICE

08-12-2013

In final draft guidance issued on Friday, the UK drugs watchdog the National Institute for Health and…

AubagioEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofiUK

COMPANY SPOTLIGHT

Menarini

Back to top